Beyond the core acquisition terms, Alcon’s deal framing ties its surgical retina distribution model to Neurotech’s implant-based cell therapy Encelto. The company emphasized how Encelto’s encapsulated delivery mechanism—releasing rhCNTF—creates an “implantable therapeutic” that differs from recurring dosing paradigms. The acquisition coverage also highlighted the therapy’s FDA pathway, including priority review and orphan drug designation prior to approval in March 2025. Alcon described the acquisition as a milestone to broaden patient access within the MacTel community. The deal context matters because it illustrates how large ophthalmic platforms are building long-duration differentiation via biomanufacturing-linked assets, not just drug portfolios. Alcon positioned the collaboration as an effort to scale access and global availability. For the biotech value chain, the strategic integration emphasizes that cell therapy commercialization depends on manufacturing scale, surgical adoption, reimbursement strategy, and lifecycle management—especially for implantable products.